News and Announcements
Capitalizing on Megatrends in Public Markets
- Published November 03, 2022 7:29AM UTC
- Publisher Maan Perez
- Categories Venture Investor Interviews
Often, public markets host technology-based companies that are riding the waves of megatrends and therefore deliver remarkable returns. However, identifying these trends, then assessing the businesses within them, is a task that takes some sophistication and experience.
Watch this panel as we explore the ins and outs of capitalising on these megatrends in public markets from our esteemed panel of analysts and fund managers.
Panelists:
Jun Bei Liu – Portfolio Manager at Tribeca Investment Partners
Paul Rayson – CEO at Hearts and Minds Investments
Roy Chen – Founder at RC Global Funds Management
Niv Dagan – Founder & Executive Director at Peak Asset Management
Looking for new investment opportunities? Click here to browse hundreds of companies, connect with their CEO and create your personalised deal flow.
Your AI Driven matchmaking platform
With a 14-year track record, a network of 32,000+ investors, and a capital raising platform, Wholesale investor is a leading investment platform for start-ups, scale-ups, emerging growth companies, and small caps.
Venture Investor Interviews
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
